67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin's lymphoma.
暂无分享,去创建一个
G. Denardo | S. Denardo | S. Shen | D. Kukis | C. Meares | D. DeNardo
[1] G. Denardo,et al. 67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] J. McGahan,et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Lamborn,et al. Comparison of 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2-iminothiolane-2-[p-(bromoacetamido)benzyl]-DOTA-ChL6 in breast cancer xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] G. Denardo,et al. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study. , 1998, Anticancer research.
[5] G. Denardo,et al. Impact of splenomegaly on therapeutic response and I‐131‐LYM‐1 dosimetry in patients with B‐lymphocytic malignancies , 1997, Cancer.
[6] F. Buchegger,et al. Comparison of copper-67- and iodine-125-labeled anti-CEA monoclonal antibody biodistribution in patients with colorectal tumors. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] H. Amstutz,et al. Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] K. Lamborn,et al. Reproducibility of operator processing for radiation dosimetry. , 1997, Nuclear medicine and biology.
[9] A. Introduction. RELEASE OF PATIENTS ADMINISTERED RADIOACTIVE MATERIALS , 1997 .
[10] K. Lamborn,et al. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. , 1996, Journal of Nuclear Medicine.
[11] A. Gunasekera,et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10 , 1996, Cancer Immunology, Immunotherapy.
[12] G. Denardo,et al. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. , 1996, Nuclear medicine and biology.
[13] I. Bernstein,et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. , 1996, Cancer research.
[14] G. Denardo,et al. Radioimmunotherapy: recent results and future directions. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Srivastava. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. , 1996, Cancer biotherapy & radiopharmaceuticals.
[16] T. Wheldon,et al. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] G. Denardo,et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. , 1995, Cancer research.
[18] H. Amstutz,et al. Cellular processing of copper-67-labeled monoclonal antibody chCE7 by human neuroblastoma cells. , 1995, Cancer research.
[19] G. Griffiths,et al. Processing of antibody‐radioisotope conjugates after binding to the surface of tumor cells , 1994, Cancer.
[20] G. Denardo,et al. A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates , 1994, Cancer.
[21] R. Stahel,et al. A comparison of 67Cu‐ and 131I‐labelled forms of monoclonal antibodies SEN7 and SWA20 directed against small‐cell lung cancer , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[22] P. Schubiger,et al. Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35. , 1993, Cancer research.
[23] D. Kukis,et al. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals , 1993 .
[24] G. Denardo,et al. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies. , 1993, Nuclear medicine communications.
[25] S. Srivastava,et al. Selection of radionuclides for radioimmunotherapy. , 1993, Medical physics.
[26] S. Srivastava,et al. Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[27] J. Fowler. Radiobiological aspects of low dose rates in radioimmunotherapy. , 1990, International journal of radiation oncology, biology, physics.
[28] G. Denardo,et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. , 1990, Cancer research.
[29] S. Larson,et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[30] S. Martin,et al. A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignancies , 1989, Hematological oncology.
[31] S. Denardo,et al. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. , 1985, Analytical biochemistry.
[32] C. Zanelli,et al. Radiation absorbed dose estimates at the cellular level for some electron-emitting radionuclides for radioimmunotherapy. , 1984, The International journal of applied radiation and isotopes.
[33] J. L. Coffey,et al. Calculating dose from remaining body activity: a comparison of two methods. , 1979, Medical physics.
[34] Ws Snyder,et al. MIRD Pamphlet #11: S, Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs , 1975 .
[35] V. Courtenay. Radioresistant mutants of L5178Y cells. , 1969, Radiation research.
[36] L. T. Dillman. Radionuclide decay schemes and nuclear parameters for use in radiation-dose estimation. , 1969, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.